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ABSTRAK 
Pengenalan dan objektif: Dalam tahun-tahun kebelakangan ini, “double hit” dan 
“double protein” melibatkan penyusunan semula gen dan ekspresi protein MYC dan 
BCL2 dan/atau BCL6 adalah ungkapan yang paling banyak digunakan untuk 
menggambarkan faktor prognostik di dalam “diffuse large B-cell lymphoma (DLBCL)”. 
Kajian ini adalah untuk menentukan kekerapan ekspresi „double/triple protein 
lymphoma” dengan menggunakan immunohistokimia dan mengaitkan keputusannya 
dengan ciri-ciri klinikopatologikal dan klasifikasi sel asal.   
 
Bahan dan kaedah: Kami telah menjalankan satu kajian keratan rentas dengan 
menggunakan 29 blok tisu parafin kes DLBCL. Semua sampel telah dinilai untuk 
ekspresi protein-protein MYC, BCL2 dan BCL6 oleh immunohistokimia. Di samping 
itu, subkumpulan daripada COO DLBCL telah ditentukan oleh ekspresi CD10, BCL6 
dan MUM1 berdasarkan klasifikasi Hans. 
 
Keputusan: Antara 29 kes, MYC, BCL2 dan BCL6 protein masing-masing telah 
dikesan dalam 72.4%, 62.1% dan 62.1% daripada pesakit.  Ekspresi serentak (Positif 
MYC/ positif BCL2 dan/atau positif BCL6) dikesan di dalam 58.6% pesakit. 34.5% 
dikategorikan sebagai subkumpulan “germinal centre like (GCB)” dan 65.5% 
dikategorikan sebagai subkumpulan “non germinal centre like (non-GCB) subgroup“. 
Antara ciri-ciri klinikopatologikal,  “double/triple protein lymphoma” telah dikaitkan 
dengan ketara dengan peningkatan kadar LDH (p=0.018), skor IPI (p=0.003), penilaian 
Ann Arbor (p=0.011) dan kadar respon penuh (p=0.011). 
 xii 
Kesimpulan:  “Double/triple protein lymphoma” telah berkait rapat dengan faktor 
risiko klinikal yang lebih buruk. Oleh itu, analisis ekspresi protein MYC, BCL2 dan 
BCL6 menggunakan immunohistokimia adalah pendekatan yang pantas dan murah 
untuk menstratifikasikan risiko pesakit pada masa didiagnosakan. 
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ABSTRACT 
Background and objective: In recent years, “double hit” and “double protein” 
involving gene rearrangement and protein expression of MYC and BCL2 and/or BCL6 
are the most used terms to describe poor prognostic factors in diffuse large B-cell 
lymphoma (DLBCL) This current study is to determine the frequency of double or 
triple protein expression by using immunohistochemistry (IHC) and relating the result 
with clinicopathological features and cell of origin (COO) classification. 
Material and methods: We conducted a cross sectional study by using 29 archived 
formalin-fixed paraffin embedded tissue blocks of DLBCL. All the samples were 
evaluated for expression of MYC, BCL2 and BCL6 by IHC. In addition, the 
subgrouping of COO DLBCL was determined by expression of CD10, BCL6 and 
MUM1 based on Hans classification.  
 
Result: Among the 29 cases, MYC, BCL2 and BCL6 proteins were detected in 72.4%, 
62.1% and 62.1% of patients, respectively. Concurrent expression (MYC 
positive/BCL2 positive and/or BCL6 positive) was present in 58.6% of patients. 34.5% 
were categorized as germinal centre like (GCB) subgroup and 65.5% were categorized 
as non germinal centre like (non-GCB) subgroup. Among the clinicopathological 
features, the double/triple protein expression lymphoma was significantly associated 
with elevated LDH level (p=0.018), IPI score (p=0.003), Ann Arbor stage (p=0.011) 
and complete response rate (p=0.011). 
 
 
 xiv 
Conclusion: Double/triple protein lymphoma was strongly associated more adverse 
clinical risk factors. Thus, analyses of MYC, BCL2 and BCL6 expression by IHC 
represents a rapid and inexpensive approach to risk-stratify patients with DLBCL at 
diagnosis.  
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CHAPTER 1 
1.0 INTRODUCTION 
Cancer remains as one of the leading cause of death in the world. In 2008, it was 
estimated that about 12.7 million new cases and 7.6 million cancer deaths occurred 
worldwide with 56% of new cancer cases and 63% of the cancer deaths occurring in the 
less developed regions of the world (Ferlay et al., 2010). In Malaysia, cancer is also one 
of the most common causes of death. According to the National Cancer Registry, a total 
of 18,219 new cancer cases comprises of 8,123 (44.6%) males and 10,096 (55.4%) 
females were diagnosed and registered in 2007 (Zainal Ariffin and Nor Saleha, 2011). 
 
Lymphoma is one of ten leading cancers among population of Malaysia. Other cancers 
are breast, colorectal, lung, nasopharynx, cervix, leukaemia, ovary, stomach and liver.  
In 2007, a total of 776 new cases of lymphoma were reported in Malaysia comprising of 
448 males and 328 females (Zainal Ariffin and Nor Saleha, 2011). The lymphoma 
ranked sixth most common cancer among Malaysian regardless of sex, the sixth most 
common cancer among males and eighth most common cancer among females. The 
incidence of lymphoma was slightly higher among males compared to females. Chinese 
were found to have higher incidence rate compared to Malay and Indian. While in 
Kelantan, lymphoma is the fourth most common cancer type among male comprise of 
36 cases (8.33%) (Zainal Ariffin and Nor Saleha, 2011).  
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Lymphoma represents a combination of both Hogkin lymphomas (HL) and Non-
Hodgkin‟s Lymphoma (NHL).  NHL is the fifth leading type of new cancer cases 
among men and women, accounting for 4-5% of new cancer cases and 3% of cancer 
death among men and the sixth among women in the United States (Jemal et al., 2008). 
The annual incidence of NHL is estimated to be 15–20 cases/100,000 in Europe and 
USA (Fisher and Fisher, 2004).  
  
Classifying NHL can be quite confusing because there are so many types, therefore 
several different classification systems have been used before such as National Cancer 
Institute‟s Working Formulation (IWF) (Rosenberg, 1982) and Revised European-
American Classification of Lymphoid Neoplasms (REAL) (Harris et al., 1994).  
 
The most recent system used is the World Health Organization (WHO) classification. 
The WHO classification first introduced in 2001 (Jaffe, 2001) and updated in 2008 
(Swerdllow et al., 2008) which based on the principles initially defined in the Revised 
European-American Classification of Lymphoid Neoplasms (REAL). This classification 
divides Non Hodgkin Lymphoma into two groups: those of B-cell origin and those of T-
cell/natural killer (NK) cell origin. According to 2008 WHO classification, Diffuse 
Large B-cell Lymphoma (DLBCL) was classified under mature B-cell neoplasm 
(Swerdllow et al., 2008) .  Mature B cell neoplasm comprise over 90% of lymphoid 
neoplasm worldwide (Armitage and Weisenburger, 1998).   
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The aetiology of DLBCL remains unknown. In the 2008 WHO Classification, detailed 
discussion in the following morphological, biological and clinical studies have allowed 
the subdivision of DLBCL into morphological variants, molecular and 
immunophenotypic subgroups and distinct disease entities (Swerdllow et al., 2008). 
Therefore, it is not surprise that many reseachers and scientists have dedicated their 
time and money in regards to studies, experiments and reviews to understand more 
about DLBCL. 
 
The prognostic factors of DLBCL are still the hot issues for researchers. Prognostic 
factors in DLBCL can be divided into those related primarily to the patient (e.g. age and 
performance status), to the tumour itself (e.g. stage, tumour burden, proliferating 
fraction, extranodal involvement), to aggressiveness indicators (e.g. LDH serum level, 
2-microglobulin levels, proliferating fraction), and to the therapeutic strategy (Martelli 
et al., 2013). International prognostic index (IPI) based on clinical parameters is widely 
used for risk stratification but might be not reliable to predict the outcome in individual 
patients because of biological diversity of the disease (Lossos and Morgensztern, 2006).  
 
According to gene expression profile (GEP), DLBCL can be divided into germinal 
center B-cell (GCB), activated B-cell (ABC) and unclassified subtypes (Alizadeh et al., 
2000; Rosenwald et al., 2002; Wright et al., 2003). These molecular subtypes are 
associated with different outcomes, even after the introduction of immunochemotherapy 
(Fu et al., 2008; Lenz et al., 2008). GEP is not availabe in most clinical laboratories, 
therefore different approached or algorithms with small panels of biomarker have been 
developed to translate the robust information from molecular studies into a routine 
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clinical platform (Colomo, 2003; Hans et al., 2004; Muris et al., 2006; Choi et al., 
2009; Meyer et al., 2010). 
 
Double-hit (DH) lymphomas are intriguing subset that is defined by a chromosomal 
breakpoint affecting the MYC/8q24 locus in combination with another recurrent 
breakpoint. Most commonly is MYC+/BCL2+. MYC+/BCL6+ DH lymphomas are 
relatively rare, and most of these cases represent BCL2+/BCL6+/MYC+ triple-hit 
lymphoma (Aukema et al., 2011). Notably, DLBCL with translocation of both MYC 
and BCL2 is characterized by poor response to standard therapy and has an aggressive 
clinical course (Snuderl et al., 2010; Johnson et al., 2012).    
 
To date, there has no tissue study of classifying pre-treatment DLBCL into GCB and 
ABC, and more of the double-hit/triple-hit, in correlation with the prognosis in DLBCL 
cases diagnosed in Hospital Universiti Sains Malaysia. From this study, it is hoped that 
it will be a starting point of using immunohistochemistry to classify DLBCL into 
germinal center B-cell (GCB) or activated B-cell (ABC) group, followed by testing of 
double/triple-hit when the diseases is resistant to the first line treatment.  
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CHAPTER 2 
2.0 LITERATURE REVIEW 
2.1 DEFINITION AND INCIDENCE OF DIFFUSE LARGE B-CELL 
LYMPHOMA 
Diffuse Large B-cell Lymphoma (DLBCL) is a neoplasm of large B lymphoid cells 
with nuclear size equal to or exceeding nomal macrophage nuclei or more than twice 
the size of a normal lymphocyte, that has a diffuse growth pattern (Swerdllow et al., 
2008). DLBCL is the most common type of Non-Hodgkin Lymphoma in adults, 
accounting for 31% of all Non Hodgkin Lymphoma in Western Countries (Armitage, 
1997; Swerdllow et al., 2008). In Malaysia, higher proportion was reported of 
approximately 60% (Chai et al., 1999; Peh et al., 2003). 
 
The median age is in 7th decade although other types of aggressive Non-Hodgkin 
lymphoma (NHL) present at a lower median age, as for instance Burkitt lymphoma and 
primary mediastinal lymphoma (Smith et al., 2011). DLBCL is the common lymphoid 
malignancy in adults (Armitage, 1997) but it may also occur in children and young 
adults. It is slightly common in males than in females. The probability of having 
DLBCL increases with age, from 0.13% and 0.09% before the age of 29 to 1.77% and 
1.4% after the age of 70 in men and women, respectively (Sarkozy and Coiffier, 2013).  
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The aetiology of DLBCL remains unknown. It may arise as primary or de novo, or may 
results from a transformation of an indolent lymphoma eg chronic lymphocytic 
leukaemia/small lymphocytic leukaemia (CLL/SLL), follicular lymphoma, marginal 
zone lymphoma or nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) 
(Swerdllow et al., 2008). 
 
2.2 THE CLINICAL FEATURES AND MORPHOLOGY OF DIFFUSE LARGE 
B-CELL LYMPHOMA 
The clinical presentation of DLBCL is diverse and depends on the site of disease 
involvement. DLBCL can develop at either nodal or extra-nodal sites. Extranodal 
involvement is common and is seen in up to one-third of patients at the time of 
diagnosis (López-Guillermo et al., 2005). The most common extranodal presentation is 
in the gastrointestinal tract (stomach and ileocoecal region) but virtually any extranodal 
location may be a primary site. Other common sites of extranodal presentation include 
bone, testis, spleen, Waldeyer ring, salivary gland, thyroid, liver, kidney and adrenal 
gland. DLBCL is an aggressive disease, with the tumor showing a rapid growth rate, 
and patients present with rapid enlarging tumor masses infiltrating tissues or obstructing 
other organs, resulting in other symptoms (Swerdllow et al., 2008).  
 
Most Diffuse Large B-cell lymphoma (DLBCL) patients are asymptomatic but when 
symptoms are present they are highly dependent on the site of involvement (Armitage, 
1997). Diffuse Large B-cell lymphoma (DLBCL) patients often present with B-
symptoms including fever (≥38.5◦C), nights sweats, and weight loss (≥10% of the body 
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weight over 6 months) (Fameli-Pavlaki, 2005). Other symptoms reported by lymphoma 
patients include pruritus, fatigue, abdominal pain (enlarged spleen, liver, or bulky 
lymph node mass), bone pain (bone destruction or diffuse marrow involvement), 
neuropathic pain (nerve root compression, nerve infiltration, meningeal involvement, 
cord compression), and back pain (retroperitoneal lymph node involvement) (Armitage 
and Weisenburger, 1998).  
 
DLBCL has a diverse cytomorphology. In DLCBL not otherwise specified (NOS), three 
common and additional minor morphological variants have been recognized which are 
centroblastic, immunoblastic, anaplastic variant and rare mophologic variant 
(Swerdllow et al., 2008).  DLBCL NOS usually consists of a mixture of centroblasts 
and immunoblasts that grow diffusely, partly or completely effacing the normal 
structure of the involved organ(s) (Martelli et al., 2013).  
 
Centroblasts are defined as medium sized to large lymphoid cells with a central oval to 
round nucleus, vesicular nuclei containing finely dispersed chromatin, two to four 
nuclear membrane bound nucleoli, and usually scanty and amphophilic to basophilic 
cytoplasm. Immunoblasts have a single centrally located nucleolus and an appreciable 
amount of basophilic cytoplasm with a more or less pronounced Golgi area. 
Immunoblasts may show aspect of plasmacytoid differentiation. Clinical and/or 
immunophenotypic findings may be essential in differentiating this variant from 
extramedullary involvement by a plasmablastic lymphoma or an immature plasma cell 
myeloma. Other morphologic variants are anaplastic large cell which characterized by 
large to very large round, oval or polygonal cells with bizzare pleomorphic nuclei that 
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resemble, at least in part, Hodgkin and/or Reed Sternberg cells, and may resemble 
tumour cells of anaplastic large cell lymphoma (Swerdllow et al., 2008). The cells may 
show intrasinusoidal diffusion and cohesive growth pattern and may mimic 
undifferentiated carcinoma. On rare occasions, DLBCL with myxoid or fibrillary 
features or even consisting of spindle-shaped or signet-ring-like cells are encountered 
that represent a diagnostic challenge for the pathologist. All variants may be admixed 
with a high number of reactive T-cells and/or histiocytes. These cases should not be 
categorized as T-cell/histiocyte-rich large B-cell lymphoma as long they do not fullfil 
all the criteria of this T-cell/histiocyte-rich large B-cell lymphoma subtype (Swerdllow 
et al., 2008; Martelli et al., 2013). 
   
2.3 CLASSIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA 
Diffuse large B-cell lymphoma (DLBCL) encompasses a biologically and clinically 
diverse set of diseases (Alizadeh et al., 2000). Based on morphological, biological and 
clinical studies, DLBCL has been subdivided into morphological variants, molecular 
and immunophenotypic subgroups and distinct disease entities. However, a large 
number of cases still remain biologically heterogeneous, for which there are no clear 
and accepted criteria for subclassification: these are collectively termed Diffuse Large 
B-cell lymphoma (DLBCL), not otherwise specified (NOS). 
 
The most recent classification used for Diffuse Large B-cell lymphoma (DLBCL) is the 
World Health Organization (WHO) classification. Prior to that, there have been many 
other classifications for lymphoma, such   as National Cancer Institute‟s Working 
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Formulation (IWF) (Rosenberg, 1982) and Revised European-American Classification 
of Lymphoid Neoplasms (REAL) (Harris et al., 1994). The National Cancer Institute‟s 
Working Formulation (IWF), originally proposed in 1982, classified and grouped 
lymphomas by morphology and clinical behavior (ie, low, intermediate, or high grade) 
with 10 subgroups labeled A to J. In 1994, the Revised European-American Lymphoma 
(REAL) classification attempted to apply immunophenotypic and genetic features in 
identifying distinct clinicopathologic NHL entities. This classification divides NHL into 
two groups: those of B-cell origin and those of T-cell/natural killer (NK)–cell origin.  
 
The World Health Organization (WHO) classification, first introduced in 2001 and 
updated in 2008, further elaborates upon the Revised European-American Lymphoma 
REAL approach. According to fourth edition of the WHO Classification of 
Haematopoietic and Lymphoid Tumours 2008, they have been subdivided into four 
categories, some of which not quoted in previous schemes: (a) DLBCL – not otherwise 
specified (DLBCL, NOS), (b) DLBCL subtypes (c) Other large B-cells d) Borderline 
cases. Each category includes morphologic and/or clinico-pathologic variants that make 
the organization of these neoplasms quite complex (Table 2.1). Identifying distinctive 
subgroups within the DLBCL category can assist with prognostication and therapeutic 
strategy (Visco et al., 2013).  
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TABLE 2.1: Diffuse large B-cell lymphoma: variant, subgroup and 
subtypes/entities. (Source: Swerdllow et al., 2008).  
 
Diffuse large B-cell lymphoma (DLBCL), Not Otherwise Specified (NOS) 
  Common Morphologic variants 
      Centroblastic 
      Immunoblastic 
      Anaplastic 
  Rare morphologic variant 
  Molecular subgroups 
      Germinal centre B-cell like (GCB) 
      Activated B-cell-like (ABC) 
  Immunohistochemical subgroup 
      CD5-positive DLBCL 
      Germinal centre B-cell-like (GCB) 
      Non-germinal centre B-cell-like (non-GCB) 
 
Diffuse large B-cell lymphoma subtypes 
    T-cell/histiocyte rich large B-cell lymphoma 
    Primary DLBCL of the CNS 
    Primary cutaneous DLBCL, leg type 
    EBV positive DLBCL of the elderly 
 
Other lymphoma of large B cells 
     Primary mediastinal (thymic) large B cell lymphoma 
    Intravascular large B-cell lymphoma 
    DLBCL associated with chronic inflammation 
     Lymphomatoid granulomatosis 
   ALK positive large B-cell lymphoma  
    Plasmablastic lymphoma 
    Large B-cell lymphoma arising in HHV8 associated with multicentric 
Castleman disease 
    Primary effusion lymphoma 
 
Borderline cases 
    B-cell lymphoma, unclassifiable, with features intermediate between diffuse 
large B-cell lymphoma and Burkitt lymphoma  
    B-cell lymphoma, unclassifiable, with features intermediate between diffuse 
and large B-cell lymphoma and classical Hodgkin lymphoma 
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2.4 MOLECULAR CLASSIFICATION OF DIFFUSE LARGE B-CELL 
LYMPHOMA  
A cell of origin (COO) model based on gene expression profile (GEP) by using a cDNA 
microarray was developed to classify Diffuse Large B-cell lymphoma (DLBCL) into 
three prognostically significant subgroups; germinal center B-cell-like (GCB), activated 
B-cell-like (ABC) and unclassified subtypes which are believed to represent lymphomas 
arising from different stages of lymphoid differentiation (Figure 2.1) (Alizadeh et al., 
2000; Rosenwald et al., 2002; Wright et al., 2003).  
 
The GCB and ABC subtypes have unique gene expression signatures. ABC subtypes 
was characterized by constitutive NF-κB activation, whilst the GCB is associated with 
BCL2 gene rearrangement t(14;18)(q32;q21) (Huang et al., 2002; Iqbal et al., 2004). 
The rearrangement of BCL6, expressed by germinal centre B- cells, is also important 
for GCB (Martelli et al., 2013).  
 
Currently it is impractical to perform microaaray analysis on every patient with 
DLBCL. Because of this, various immunohistochemical algorithms have been 
developed to predict the cells of origin and/or survival including Hans, Modified Hans, 
Choi, Modified Choi, Muris, Nyman and Tally algorithm, (Figure 2.2) (Colomo, 2003; 
Hans et al., 2004; Muris et al., 2006; Choi et al., 2009; Meyer et al., 2010). These 
algorithms use different combinations of antibodies eg CD10, BCL6 and MUM1/IRF4, 
GCET1, FOXP1 and LMO2 to detect germinal center or activated B-cell–related 
proteins. 
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Figure 2.1. Key oncogenic pathways in DLBCL. (Souce: Sehn and Gascoyne, 
2015). 
Note: The 2 major molecular subtypes of DLBCL are shown: the GCB and the ABC type. Both 
tumors arise from stages of differentiation reminiscent of germinal center B cells. The GCB 
subtype arises from centroblasts, whereas the ABC subtype arises from a plasmablastic cell just 
prior to germinal center exit. The main oncogenic pathways are listed, as well as the recurrent 
mutations, gains and losses of genetic material, and characteristic translocations that underlie these 
pathway perturbations. In bold are oncogenic mechanisms that are preferentially found in 1 
molecular subtype. Cb, centroblast; Cc, centrocyte; Pb, plasmablast; Pc, plasma cell; DHIT, 
double-hit lymphoma; del, deletion; BCR, B-cell receptor.  
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The results of the algorithms developed by Hans et al (2004) and Choi et al (2009) have 
correlated well with the corresponding GEP results and have also demonstrated clear 
survival differences between the germinal center B-cell-like (GCB) and non- germinal 
center B-cell-like (non-GCB) Diffuse Large B-cell lymphoma groups (Hans et al., 
2004; Choi et al., 2009). The results of algorithms developed by other authors have not 
been compared with the corresponding GEP results and rely predominantly on survival 
differences between the immunophenotypic groups (Muris et al., 2006; Natkunam et 
al., 2008; Nyman et al., 2009).  
 
Meyer et al. (2010) found the Choi algorithm and Hans algorithm had high concordance 
with the microarray results. In this study, modifications of the Choi and Hans 
algorithms for ease of use by removing the BCL6 immunostain also showed high 
concordance with the microarray results. Immunostain for BCL6 are technically 
difficult to perform and result in difficulties in interpretation (De Jong et al., 2007). 
However the most extensively used and validated immunohistochemical model is the 
Hans classifier (Hans et al., 2004).  
 
According to Hans classification, the cases were classified into 2 groups: Germinal 
Center B-cell-like (GCB) and non-Germinal Center B-cell-like (non-GCB) by using 
CD10, BCL6 and MUM1. BCL6 and CD10 are markers of germinal center B cells 
(Flenghi et al., 1996; Dogan et al., 2000; Falini et al., 2000) whereas MUM1 is 
expressed in plasma cells and the later stages of B-cell development (Falini et al., 
2000), and it is associated with the ABC group in gene expression profiling studies 
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(Rosenwald et al., 2002). The cases were assigned to the GCB group if CD10 alone was 
positive or if both BCL6 and CD10 were positive. If both BCL6 and CD10 were 
negative, the case was assigned to the non-GCB subgroup. If BCL6 was positive and 
CD10 was negative, the expression of MUM1 determined the group: if MUM1 was 
negative, the case was assigned to the GCB group; if MUM1 was positive, the case was 
assigned to the non-GCB group. 
 
Microarray analysis has shown that patient with DLBCL expressing a GEP of GCB 
have a better and longer survival than those with a GEP of ABC (Alizadeh et al., 2000; 
Lenz et al., 2008).  
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Figure 2.2: Immunohistochemical algorithm used in Meyer et al., 2010. (Source: 
Meyer et al., 2010).  
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2.5 PRE-TREATMENT EVALUATION, STAGING AND PROGNOSTIC 
FACTORS OF DIFFUSE LARGE B-CELL LYMPHOMA  
The diagnosis of Diffuse Large B-cell lymphoma (DLBCL) includes an excision biopsy 
to assess the tumor architecture and providing adequate specimen for phenotypic and 
molecular studies. Needle core biopsy is only recommended in patients in whom a 
surgical approach is not possible or advised. Fine needle biopsy is not recommended 
(Parker et al., 2010). Once the diagnosis has been established the first critical step is the 
pre-treatment evaluation and staging.  
 
In pre-treatment evaluation, a complete history and physical examination are the two 
important components. Physical examination includes evaluation of all lymph nodes 
enlargement, site and size of all abnormal lymph nodes, evaluation of the presence or 
absence of hepatosplenomegaly, inspection of the skin, and detection of other palpable 
masses. The assessment of the extranodal involvement is important because extranodal 
involvement affects the prognosis of patients who are undergoing R-CHOP therapy for 
DLBCL (Takahashi et al., 2012). The presence or absence of B symptoms and other 
symptoms that may show specific sites of involvement should be noted (Martelli et al., 
2013).  
 
An assessment of performance status is also important in all patients, and especially for 
those who are entering into clinical research trials. There are various scoring systems 
used. The most generally used are Eastern Cooperative Oncology Group (ECOG) score 
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(Oken et al., 1982) (Table 2.2) and Karnofsky score (Karnofsky et al., 1948). In our 
study, we used ECOG score in view of its simplicity over the Karnofsky score. 
 
Table 2.2: Eastern Cooperative Oncology Group (ECOG) score. (Source: Oken et 
al., 1982).  
ECOG PERFORMANCE STATUS 
GRADE ECOG 
0 Asymptomatic (Fully active, able to carry on all predisease activities 
without restriction) 
1 Symptomatic but completely ambulatory (Restricted in physically 
strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature. For example, light housework, office work) 
2 Symptomatic, <50% in bed during the day (Ambulatory and capable of 
all self care but unable to carry out any work activities. Up and about 
more than 50% of waking hours) 
3 Symptomatic, >50% in bed, but not bedbound (Capable of only limited 
self-care, confined to bed or chair 50% or more of waking hours) 
4 Bedbound (Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair) 
5 Death 
 
Laboratory investigations that should be routinely performed in DLBCL patients 
include a complete blood count to assess bone marrow reserves and a white blood cell 
differential with careful examination of the peripheral blood to look for the presence of 
circulating lymphoma cells. Serum chemistry should include an assessment of hepatic 
and renal function. Lactate dehydrogenase (LDH) is an important indicator of tumour 
activity and is included as prognostic factors in the International Prognostic Index 
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(Shipp et al., 1993).  Based on our centre, Hospital Universiti Sains Malaysia, the 
normal range of LDH level is < 480 U/L. The uric acid level may predict patients at 
increased risk for urate nephropathy. A test for a complete assessment of HIV, HBV, 
and HCV should also be performed in all patients. Where treatment is considered, bone 
marrow biopsy with or without aspirate is essential (Martelli et al., 2013). 
 
The standard staging system used for Diffuse Large B-cell lymphoma (DLBCL) is Ann-
Arbor classification system which was proposed at the Ann Arbor Conference in 1971 
(Carbone et al., 1971) and the Cotswolds modification (Lister et al., 1989) (Table 2.3). 
This staging system reflects the number of sites of involvement and their relation to the 
diaphragm, the existence of B symptoms (fevers >38 ◦C for at least three consecutive 
days, night sweats, body weight loss >10% during the 6 months prior to diagnosis) and 
the presence of extranodal disease.  
 
 
 
 
 
 
 
 
 
 
 
 19 
Table 2.3: Ann Arbor Classification and the Cotswold Modifications. (Source:  
Armitage, 2005).  
STAGE FEATURES 
I 
Involvement of a single lymph node region or lymphoid structure 
(eg, spleen, thymus, Waldeyer‟s ring)  
II 
Involvement of two or more lymph node regions on the same side 
of the diaphragm 
III  
Involvement of lymph regions or structures on both sides of the 
diaphragm 
 IV Involvement of extranodal site(s) beyond that designated E  
For all stages  
 
A  No symptoms  
B  
Fever (38
o
C), drenching sweats, weight loss (10% body weight 
over 6 months)  
 
 
For Stages I 
to III  
Involvement of a single, extranodal site contiguous or proximal to 
known nodal site 
E 
 
Cotswold 
modifications  
Massive mediastinal disease has been defined by the Cotswold 
meeting as a thoracic ratio of maximun transverse mass diameter 
greater than or equal to 33% of the internal transverse thoracic 
diameter measured at the T5/6 intervertebral disc level on chest 
radiography.  
  
The number of anatomic regions involved should be indicated by 
a subscript (eg, II3) 
 
Stage III may be subdivided into: III1, with or without plenic, 
hilar, celiac, or portal nodes;III2, with para-aortic, iliac, 
mesenteric nodes 
 
Staging should be identified as clinical stage (CS) or pathologic 
stage (PS)  
 
A new category of response to therapy, unconfirmed/uncertain 
complete remission (CR) can be introduced because of the 
persistent radiologic abnormalities of uncertain significance 
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The Ann Arbor staging system does not adequately provide prognostic information for 
many subtypes of Non-Hodgkin Lymphoma and is far from optimal making treatment 
decisions (Armitage, 1997). Most non-Hodgkin Lymphomas are not localized and the 
ability to better assess the majority of patients for treatment decisions and to stratify 
patients in clinical trials is extremely important. Thus, in 1993, the International Non-
Hodgkin Lymphoma Prognostic Index (IPI) was published (Shipp et al., 1993) to aid in 
predicting the prognosis of patients with aggressive non-Hodgkin's lymphoma (Table 
2.4). This was the result based on an international collaboration that involved 2031 
patients with aggressive non-Hodgkin Lymphoma, treated with an anthracycline-based 
combination chemotherapy regimen. Although originally intended for the use in 
patients with aggressive lymphomas, this prognostic index has utility for all types of 
non-Hodgkin Lymphoma and has been widely applied. Results of the IPI study showed 
that five factors were roughly equal in power in predicting treatment outcome. These 
included age (≤ 60 years vs > 60 years), lactate dehydrogenase (LDH) value (≤ upper 
limit of normal [ULN] vs > ULN), performance status (ECOG) 0, 1 vs > 1), Ann Arbor 
stage (I/II vs III/IV), and the number of extranodal involvements (0, 1 vs > 1). The 
original publication suggested the patients be lumped into groups with a low risk (ie, 
score of 0 or 1), low intermediate risk (score of 2), a high intermediate group (score of 
3), and a high risk (score of 4 or 5). An age-adjusted model or known as age-adjusted 
IPI (aaIPI) was also constructed for younger patients aged ≤60 years (Table 2.4).  
 
In the original study and in previous experience, there is a highly significant impact on 
chances to achieve a remission, remain in remission, and overall survival based on the 
IPI score. For example, patients in the low-risk group in the original publication had an 
87% complete remission rate and an overall survival of 73% at 5 years versus a 44% 
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complete remission rate and 26% survival at 5 years in the high- risk group (Shipp et 
al., 1993). 
Table 2.4: International Prognositic index (IPI). (Source: Martelli et al., 2013)  
IPI    aa-IPI    
Risk group  IPI factors  Risk group  IPI factors  
Low 0 or 1  Low 0 
Low intermediate    2 Low intermediate    1 
High intermediate 3 High intermediate 2 
High 4 or 5 High 3 
IPI Factors                                                                                                            
Older than 60 years of age (not used for aa-IPI) 
Disease stage III/IV 
Lactate dehydrogenase level elevated                                                                                          
ECOG performance score ≥ 2 
Extranodal disease > 1 site (not used for aa-IPI) 
 
18Fluorodeoxyglucose Positron Emission Tomography (PET) scan is a noninvasive, 3-
dimensional imaging modality that has become a standard procedure both for staging 
and response assessment. Many studies showed that PET scan at the end of treatment is 
highly predictive of progression-free survival (PFS) and overall survival (OS) in 
aggressive lymphomas with or without residual masses detected with CT scan (Juweid 
et al., 2007; Seam et al., 2007; Cheson, 2009). PET scan is able to distinguish between 
lymphoma and necrosis or fibrosis in residual masses. The combination of International 
Workshop Criteria (IWC) and PET were evaluated in a retrospective analysis of 54 
patients with Non-Hodgkin Lymphoma. Based on Juweid et al. (2007) study, the 
International Harmonization Project has provided new recommendations for response 
criteria for aggressive malignant lymphomas, incorporating PET into the definition of 
response at the end of treatment. DLBCL arisen in particular extranodal sites require 
further “specific” staging studies that vary somewhat by site. This is important in 
primary CNS Lymphoma (Ferreri and Reni, 2007) testicular DLBCL (Zucca et al., 
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2003) and gastric DLBCL (Ferreri and Montalbán, 2007).  
 
2.6 DOUBLE OR TRIPLE HIT LYMPHOMA 
Double hit (DH) or also referred as “Dual Hit” lymphomas are intriguing subset that is 
defined by a chromosomal breakpoint affecting the MYC/8q24 locus in combination 
with another recurrent breakpoint. Most commonly is MYC+/BCL2+ which involving 
the BCL2 at t(14; 18)(q32;q21). BCL6+/MYC+ DH lymphomas are relatively rare, and 
most of these cases represent BCL2+/BCL6+/MYC+ are of triple-hit lymphomas 
(Aukema et al., 2011).  
  
Approximately a third of DLBCL cases harbor a BCL2 or BCL6 rearrangement, MYC 
rearrangements are less common and detected by fluorescent in situ hybridization 
(FISH) in 5 to 14 % of cases (Iqbal et al., 2004; Barrans et al., 2010). Green et al. 
(2012) reported approximately 5% of DLBCL are double-hit lymphomas, which 
involved translocation of both MYC and BCL2.  
 
Majority cases with DH lymphoma having a germinal center phenotype and expression 
of BCL2. Patients with DH lymphomas often presented with poor prognostic 
parameters, including elevated LDH, bone marrow and CNS involvement, and a high 
IPI score (Aukema et al., 2011).  
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DLBCL cases that harbor a BCL2 or BCL6 rearrangement alone have not been 
associated with a worse outcome compared to cases without these rearrangements. 
However, several reports have demonstrated that a MYC rearrangement confers a worse 
prognosis following treatment with CHOP or R- CHOP (Savage et al., 2016). DLBCL 
with translocation of both MYC and BCL2 (double-hit lymphoma) has poor response to 
standard therapy and has an aggressive clinical course (Johnson et al., 2009; Snuderl et 
al., 2010; Li et al., 2012).  
 
More recently, others have extended the concept of MYC/BCL2 double-hit lymphoma 
by assessing for MYC and BCL2 protein expression by immunohistochemistry (IHC), 
the logic being that protein expression, regardless of mechanisms, may have prognostic 
significance (Green et al., 2012; Johnson et al., 2012; Kluk et al., 2012). These studies 
were possible because of the recent availability of anti-MYC antibodies and anti-BCL2 
antibodies which suitable for IHC staining in paraffin-embedded tissues. These IHC 
markers are easier to perform, especially in centres without the facilities of fluorescent 
in situ hybridization (FISH) or other molecular techniques. This technique also can 
identify DLBCL patients who have a high likelihood of demonstrating an unsatisfactory 
response to standard treatment and who could be candidates for novel therapeutic 
strategies (Green et al., 2012).  
 
In two studies, Green et al (2012) and Johnson et al (2012) showed that DLBCL 
patients with MYC/BCL2 coexpression, with or without MYC or BCL2 gene 
rearrangements, have a poorer prognosis with inferior overall survival and progression-
free survival. However most of the cases with double protein expressor or double 
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protein lymphoma (DPL) (overexpression MYC and BCL2) are without translocation. 
Unlike classic double-hit DLBCL, double protein expressor DLBCL is much more 
prevalent (~30% vs 5% of DLBCL) and two-thirds of patients are ABC subtype or non-
GCB subtype (Figure 2.3), depending on the platform used to establish cell of origin 
(COO) (Green et al., 2012; Johnson et al., 2012; Horn et al., 2013; Hu et al., 2013).  
 
FIGURE 2.3: The relationship of cell of origin and high BCL2 and MYC 
expression in Diffuse Large B-cell lymphoma (DLBCL). Most cases of double-hit 
lymphoma are of germinal center B cell (GCB) origin whereas most cases of 
double-expresser lymphomas, without any hits, are of activated B cell (ABC) 
origin. (Source: Dunleavy, 2015).  
 
